Nanofactory for Metabolic and Chemodynamic Therapy: Pro-Tumor Lactate Trapping and Anti-Tumor ROS Transition

Ruiqing He
Tongji University

Jie Zang
Tongji University

Yuge Zhao
Tongji University

Ying Liu
Tongji University

Shuangrong Ruan
Tongji University

Xiao Zheng
Tongji University

Gaowei Chong
Tongji University

Dailin Xu
Tongji University

Yan Yang
Tongji University

Yushan Yang
Tongji University

Tingting Zhang
Tongji University

Jingjing Gu
Tongji University

Haiqing Dong
Tongji University

Yongyong Li (✉ yongyong_li@tongji.edu.cn)
Tongji University Affiliated Shanghai Pulmonary Hospital  https://orcid.org/0000-0002-6688-5978
Abstract

Lactate plays a critical role in tumorigenesis, invasion and metastasis. Exhausting lactate in tumors holds great promise for the reversal of the immunosuppressive tumor microenvironment (TME). Herein, we report on a "lactate treatment plant" (i.e., nanofactory) that can dynamically trap pro-tumor lactate and in situ transformation into anti-tumor cytotoxic reactive oxygen species (ROS) for a synergistic chemodynamic and metabolic therapy. To this end, lactate oxidase (LOX) was nano-packaged by cationic polyethyleneimine (PEI), assisted by a necessary amount of copper ions (PLNPCu). As a reservoir of LOX, the tailored system can actively trap lactate through the cationic PEI component to promote lactate degradation by two-fold efficiency. More importantly, the byproducts of lactate degradation, hydrogen peroxide (H2O2), can be transformed into anti-tumor ROS catalyzing by copper ions, mediating an immunogenic cell death (ICD). With the remission of immunosuppressive TME, ICD process effectively initiated the positive immune response in 4T1 tumor model (88% tumor inhibition). This work provides a novel strategy that rationally integrates metabolic therapy and chemodynamic therapy (CDT) for combating tumors.

1. Background

The tumor microenvironment (TME) is critically important during the initiation and progression of carcinogenesis.[1] Lactate, has long been considered as the waste product of tumor aerobic glycolysis (termed as the “Warburg effect”), is now emerged as an important regulator of tumor development.[2] Increasing evidence has demonstrated that lactate act as accomplices to assist tumor immune escape and promote tumor progression, especially through suppressing the function of multiple immune cells, such as macrophages, dendritic cells (DC), effector T cells.[3–5] Therefore, to against cancer, several agents (glycolysis inhibitors (Dichloroacetate, DCA), MCT-inhibiting siRNA (siMCT-4) et al.) have been delivered via nanocarriers to inhibit lactate production and transportation.[6, 7] Lactate oxidase (LOX), catalyzing the oxidation of lactate to pyruvate, has also been harnessed for lactate degradation and TME regulation.[8–10]

The LOX delivery based on nanocarrier represents a promising approach, as it addresses the bio-stability and side effect challenges.[8] Unfortunately, it is still facing the dilemma that the inefficiency of lactate depletion in complex TME and tumor inhibition. Most current works focus on the decomposing lactate with LOX, combined with biozym (glucose oxidase, GOx) or photodynamic therapy to enhance the anti-tumor effect, in which the introduction of addition therapeutic cargo complicates the design of nanomedicine.[11, 12] From a different perspective, we propose a strategy of “turn waste into wealth”, developed to not only exhaust the lactate but also transform the hydrogen peroxide (H2O2), the byproduct of lactate degradation, into cytotoxic drugs via a catalytic medicine approach.

The decomposition of lactate with LOX produce the H2O2[13] which can be harnessed to realize Fenton reaction with Fenton agents (e.g., Cu2+, Fe3+/Fe2+) to produce more cytotoxic hydroxyl radicals (⋅OH) for tumor killing, namely chemodynamic therapy (CDT).[14] Meanwhile, excess reactive oxygen species
(ROS) induce immunogenic cancer cell death (ICD), and promote the secretion of various pro-inflamatory cytokines from immune cells (e.g., IFN-γ, IL-6, TNF), thereby enhancing the inflammatory response in tumor sites for further immune activation.[15] Since Fe$^{2+}$-catalyzed Fenton reaction efficiency was restrained by strongly acidic conditions (pH 2−4). While Cu$^{2+}$, possesses a higher reaction rate of ~160-fold of Fe$^{2+}$ in the weakly acidic and neutral media, could be a better choice.[14, 16, 17]

Accordingly, herein, we developed the “lactate treatment plant” (i.e., nanofactory) that can dynamically trap pro-tumor lactate and in situ transformation into anti-tumor cytotoxic ROS for a synergistic chemodynamic and metabolic therapy. As shown in Scheme 1, cationic polyethyleneimine (PEI), possessing robust acid trapping ability, was chosen as the carrier for loading LOX and copper ions (Cu$^{2+}$) through electrostatic interaction and coordination, named as LNP$^{\text{Cu}}$. The pH-responsive detachable polyethylene glycol (CHO-PEG-CHO) shell endows LNP$^{\text{Cu}}$ with stability and biocompatibility (PLNP$^{\text{Cu}}$). Upon acid-triggered shell shedding, lactate gathered surrounding the “nanofactory” through the “active trapping” of the exposed primary amine on PEI. Then the LOX contained in nanofactory facilitated the lactate catalysis to generate H$_2$O$_2$ which was continuously transformed into toxic $\cdot$OH through the Fenton-like reaction. In this fashion, the lactate depletion by the cascade catalysis process reversed lactate-induced suppression of immune cells function in TME, and more importantly, its product of ROS subsequently induced ICD and anti-tumor immunity. Therapeutically, the “lactate treatment plant” significantly inhibited the growth of 4T1 breast cancer.

2. Results And Discussion

2.1. Synthesis and Characterization of PLNP$^{\text{Cu}}$

The LNP$^{\text{Cu}}$ can quickly assemble by mixing polyethyleneimine (PEI), copper ions (Cu$^{2+}$) and lactate oxidase (LOX) under gentle stirring at room temperature (see SI for the detailed description of the preparation). The driving force for the assembly was mainly electrostatic interaction and coordination among Cu$^{2+}$, PEI and LOX. The obtained LNP$^{\text{Cu}}$ have the hydrodynamic size of 115 ± 5.0 nm with a narrow polydispersity index (PDI) of 0.14 by dynamic light scattering (DLS) (Fig. S1d).

To improve the circulation stability and biocompatibility, the surface of the LNP$^{\text{Cu}}$ was shielded with polyethylene glycol derivates with the double end group of aldehyde (CHO-PEG-CHO) through pH-responsive Schiff base (named as PLNP$^{\text{Cu}}$). As shown in the $^1$H NMR spectra, the disappearance (at pH 7.4) and reappearance (at pH 6.5) of the hydrogen peak for aldehyde groups in the dotted area suggested that the acid-responsive labiality of Schiff bases formed by PEI with aldehyde groups of OHC-PEG-CHO (Fig. S4). PLNP$^{\text{Cu}}$ showed well-dispersed uniform spherical structures (Fig. 1a) with a visible PEG shell at pH 7.4 by transmission electron microscopy (TEM) (Fig. 1b). The hydrodynamic size of PLNP$^{\text{Cu}}$ was 218 ± 3.0 nm (PDI 0.06), which was consistent well with the TEM results (Fig. 1d). Notably, PLNP$^{\text{Cu}}$ exhibited the compression of zeta potential comparing with LNP$^{\text{Cu}}$ (27.07 mV vs. 18.07 mV) (Fig. 1e). However, the rebound of zeta potential from 18.07 mV to 27.50 mV (Fig. 1e) occurred at the weakly acidic condition (at
pH 6.5), indicating PEG shell could be shed from the surface of PLNP\textsuperscript{Cu} to exposure of the positive charged amino. More intuitively, the shellless PLNP\textsuperscript{Cu} upon incubated in H\textsubscript{2}O at pH 6.5 could be viewed in TEM images, as was shown in Fig. 1C and Fig. S1a.

Further, the size of PLNP\textsuperscript{Cu} was stable in neutral PBS solution within 48-hour monitoring (Fig. 1f) accompanied by a low release of LOX (26.25% ± 2.676), the content of LOX was quantified with the Bradford Protein Assay Kit according to the standard curve (Fig. S3), while the moderate LOX release behavior was found at pH 6.5 (44.74% ± 4.456) (Fig. 1h). The morphology of the PLNP\textsuperscript{Cu} at pH 5.5 was also explored (Fig. S1b), which suggested the potential for effective function exertion in the intracellular milieu. Apparently, the introduction of copper ion (with entrapment efficiency of ~81.58% determined by inductively coupled plasma mass spectrometry (ICP-MS)) may facilitate LOX loading in LNP\textsuperscript{Cu} compared with the LNP with a smaller size (Fig. S1c) which could be attributed to the coordination of metal ions (LOX%: 226.6 ± 0.518 vs. 219.7 ± 1.237 µg·mg\textsuperscript{−1}) (Fig. 1g).

2.2. Evaluation of PLNP\textsuperscript{Cu} as lactate treatment plant \textit{in vitro}

PLNP\textsuperscript{Cu}, referred to as extra/intracellular lactate treatment plant, for lactate consumption and tumor cell inhibition were investigated. As shown in Scheme 2, the lactate treatment plant elicited a chain of the response of processing lactate to antipersonnel reactive oxygen species (ROS) in the tumor cell physiology and tumor microenvironments, such as acidic microenvironment and the relatively high GSH/GSSG ratios.[18, 19] Briefly, the entire process can be categorized into three stages. First, the local high lactate concentration is formed by PEI trapping of lactate; second, lactate reacts with oxygen to produce hydrogen peroxide (H\textsubscript{2}O\textsubscript{2}) under the catalysis of LOX; finally, the Fenton-like reaction between copper ions and enzymatic product (H\textsubscript{2}O\textsubscript{2}) from the second step produced a large number of hydroxyl radicals (·OH). The verification for the above three stages was investigated as follows.

Inspired by the cationic polymer of PEI with a large number of primary amino groups, we speculated that these positive charged groups could electrostatically interact with lactate and adsorb it to the PLNP\textsuperscript{Cu} nanosystem. We thus carefully studied the adsorption behavior of PLNP\textsuperscript{Cu}. Considering the LOX may influence the determination of lactate absorption of PLNP\textsuperscript{Cu}, bovine serum albumin (BSA) was used to replace LOX, regarding their high similarity in structure and properties (isoelectric point, pl 4.7 vs. 4.6, molecular weight≈66 kDa vs. 80 kDa) except for catalysis for lactate, and was fabricated according to the synthetic procedure of LNP\textsuperscript{Cu} and PLNP\textsuperscript{Cu} (named as BNP\textsuperscript{Cu} and PBNP\textsuperscript{Cu}, respectively). Both zeta potential and hydrodynamic size of BNP\textsuperscript{Cu} and PBNP\textsuperscript{Cu} were consistent with PLNP\textsuperscript{Cu} (Fig. S2b). Subsequently, the PEI, BNP\textsuperscript{Cu}, and PBNP\textsuperscript{Cu} at different pH with equimolar amount of PEI were mixed with NaL respectively and shaken overnight at 37 °C. Followed by fully dialyzed for 4 h and the dialysate of different groups was collected for lactate analysis. The high lactate adsorption ratio of BNP\textsuperscript{Cu} (19.54% ± 0.559) and PBNP\textsuperscript{Cu} (pH=6.5) (13.56% ± 0.0284) were consistent with that of PEI solution (17.24% ± 1.07), while the PBNP\textsuperscript{Cu} (4.369% ± 0.0583) and control groups (5.804% ± 0.429) at pH 7.4 showed significantly
lower levels of lactate adsorption compared to above three groups (Fig. 2a). The above results verified that the exposure of PEI on the PLNP\textsuperscript{Cu} nanosystem played an important role in lactate recruitment, and the detachable PEG shell contributed to the shielding effect in the neutral milieu.

To evaluate the lactate consumption-ability of the nanoparticles, LNP\textsuperscript{Cu} and BNP\textsuperscript{Cu} were added into NaL solution respectively. The concentration of lactate in the mixed solution containing LNP\textsuperscript{Cu} decreased with time compared to BNP\textsuperscript{Cu} (Fig. 2b), which demonstrated the maintenance of the catalytic activity of LOX. We further studied the degradation of lactate over a short time frame (10 or 20 min) at different pH. Surprisingly, after being incubated for 20 min, the lactate degradation rate of LNP\textsuperscript{Cu} was almost four-fold higher than the free LOX group at pH 7.4 (26.16% ± 0.102 vs. 6.727% ± 0.0298), even reached the ~43 times level in 10 min of reaction (18.71% vs. 0.429%). And LNP\textsuperscript{Cu} exhibited an excellent catalytic activity even at pH 5.5 (7.977% ± 0.122) (Fig. 2c). Immediately after, the degradation ratio of lactate following 2 h exposure to LNP\textsuperscript{Cu} was studied. The result showed that the catalytic activity of LNP\textsuperscript{Cu} at different pH values (pH 7.4, 6.5, and 5.5) was significantly higher than the respective values of free LOX groups (Fig. 2d). It was speculated that the discrepancy was likely because of the adsorption effect of PEI in favor of shortening the “lactate-hunting” for LOX, and local high concentration of lactate was more favorable for the performance of enzymatic hydrolysis reaction. The above results indicated that the lactate adsorption effect of PEI contributed to the enhance of lactate degradation at different pH.

Based on the above exciting results, the third process in the lactate treatment plant that Fenton-like reaction to generate hydroxyl radical by reacting H\textsubscript{2}O\textsubscript{2} with Cu\textsuperscript{+} was explored. The concentration of H\textsubscript{2}O\textsubscript{2} was quantified via the Hydrogen Peroxide Assay Kit according to the standard curve (Fig. S5). The LOX solution was mixed with NaL solution and thoroughly reacted for 1 h at 37 °C and then the H\textsubscript{2}O\textsubscript{2} concentration of the supernatant was detected. As shown in Fig. S6, H\textsubscript{2}O\textsubscript{2} was barely detected without NaL, which has excluded the effect of residual H\textsubscript{2}O\textsubscript{2} background. And the generation of H\textsubscript{2}O\textsubscript{2} increased along with increasing NaL concentration. This directly demonstrated the LOX catalyzed reaction of Lactate + O\textsubscript{2} — pyruvate + H\textsubscript{2}O\textsubscript{2}. After that, the generation of H\textsubscript{2}O\textsubscript{2} produced by LNP\textsuperscript{Cu} at different pH conditions (pH 7.4, 6.5 and 5.5) compared with free LOX solution was recorded. The H\textsubscript{2}O\textsubscript{2} concentration was comparable in both groups which demonstrated carrier and pH change did not show interference in this process (Fig. 2e and Fig. S7). The methylene blue (MB) degradation was used to validate the Fenton-like reaction occurrence. We simulated the process of intracellular high levels of GSH (5-10 mM) induced the conversion of cupric ions (Cu\textsuperscript{2+}) to cuprous form (Cu\textsuperscript{+}), briefly, GSH was added into the supernatant of BNP\textsuperscript{Cu} and LNP\textsuperscript{Cu} solution respectively for Cu\textsuperscript{+} generation, then the H\textsubscript{2}O\textsubscript{2} and NaL solution were added in turn. The appropriate feeding amount of H\textsubscript{2}O\textsubscript{2}, GSH and NaL was identified from references.[20, 21] The reduction in absorbance of MB showed that additional lactate evoked a huge elevation of toxic ·OH in the orange group (with lactate addition) compared to light green groups (without lactate addition) (Fig. 2f). It was proven that the Cu\textsuperscript{+} resulted from GSH reduction can react with H\textsubscript{2}O\textsubscript{2} to produce ·OH since the ·OH-induced MB indicator degradation caused the change in absorbance.[20] All the results supported a well-functioning lactate treatment plant in vitro.
2.3. Intracellular behaviors of PLNP\textsuperscript{Cu}

As breast tumors exhibit immunosuppression and Warburg phenotype (with strong aerobic glycolysis induced lactate buildup), 4T1 cell line was chosen for further study.[22] We first examined the cytotoxicity of PLNP\textsuperscript{Cu} on 4T1 cells. As shown in Fig. 3a, PLNP\textsuperscript{Cu} at both low and high concentrations induced high cytotoxicity compared with the free LOX group. The higher cell viability upon treatment with PLNP\textsuperscript{Cu} (pH=7.4) suggested the protective role of the PEG shell at low concentrations. Once the acid-sensitive reaction was triggered, LNP\textsuperscript{Cu} and PLNP\textsuperscript{Cu} (pH=6.5) showed similar high efficacy for killing 4T1 cells (Fig. S9). Besides, PBNP\textsuperscript{Cu} exhibited relatively low cytotoxicity even at high concentrations (2.5 µg·mL\textsuperscript{−1}) (Fig. S8), which demonstrated that the establishment of an intracellular lactate treatment plan plays a critical role in the efficient killing of tumor cells. Then, the cellular uptake of LNP\textsuperscript{Cu} was examined by flow cytometry. 4 h of incubation with LNP\textsuperscript{Cu}@FITC appeared to reach the saturation of cellular uptake for comparable fluorescence intensity as that of 3 h, indicating that the optimal incubation time (Fig. S10). Particularly, both LNP\textsuperscript{Cu} and PLNP\textsuperscript{Cu} (pH=6.5) had similar high cellular uptakes in 4T1 cells compared to free LOX and PEG-shielded nanoparticles (PLNP\textsuperscript{Cu} pH=7.4) (Fig. 3b). Taken together, the superior cellular uptake of detached-shell PLNP\textsuperscript{Cu} and establishment of the intracellular lactate treatment plant account for the toxicity of PLNP\textsuperscript{Cu} to 4T1 cells.

Subsequently, the lactate consumption effect of PLNP\textsuperscript{Cu} was evaluated at the cellular level. Notably, the PLNP\textsuperscript{Cu} (pH=6.5) group showed the lowest levels of lactate among the experimental groups (Fig. 3c), suggesting that the lactate adsorption caused by PEI exposure on the surface of PLNP\textsuperscript{Cu} promoted the lactate consumption process, which was consistent with the functions verification results \textit{in vitro}. It also showed the potent inhibition of intra/extracellular lactate. The ·OH generation induced by PLNP\textsuperscript{Cu} was investigated using 2',7'-dichlorofluorescin diacetate (DCFH-DA) as a ROS indicator. From the fluorescent microscopy images, 4T1 cells treated with free LOX and PBS showed negligible fluorescence. And the faint fluorescence in PLNP\textsuperscript{Cu} (pH=7.4) group might be induced by the endocytosis of a small number of PLNP\textsuperscript{Cu} (Fig. 3d). In contrast, stronger green fluorescence was observed in PLNP\textsuperscript{Cu} (pH=6.5) treated cancer cells (Fig. 3d), indicating the relatively high ·OH levels rather than H\textsubscript{2}O\textsubscript{2}. Since the mean fluorescence intensity (MFI) in PLNP (pH=6.5) (the detailed information of PLNP were shown in Fig. S2a) treated 4T1 cells was insufficient as well (Fig. S11). Consistent with fluorescent microscopy images, flow cytometry results also demonstrated the critical role in triggering ·OH formation of copper ions in PLNP\textsuperscript{Cu} (Fig. 3e, f). Overall, PLNP\textsuperscript{Cu} showed the specific function to convert the lactate into the toxic ·OH product through the intracellular Fenton-like reaction, which indicated the successful construction of the intracellular lactate treatment plant.

2.4. Immunomodulatory effects on macrophages and ICD induction effects of PLNP\textsuperscript{Cu} \textit{in vitro}
·OH, a highly toxic type of ROS causes oxidative damages to lipids, proteins, and DNA which in turn result in the apoptosis of tumor cells.[23] The apoptosis and necrosis induced by PLNP\textsuperscript{Cu} of 4T1 cells were evaluated by annexin V-FITC and propidium iodide (PI) staining assay. The flow cytometry results showed that the percentage of late apoptosis and necrosis in the PLNP\textsuperscript{Cu} (pH=6.5) group (56.15%), which was nearly 2-fold than other groups (Control ~35.32%, LOX ~34.63%, PLNP\textsuperscript{Cu} pH=7.4 ~36.16%), demonstrating the build of the lactate treatment plant in tumor cells and the excellent chemodynamic therapy (CDT) performance (Fig. 4a, b).

We further investigated the immunogenic cell death (ICD) level of 4T1 cells induced by the lactate treatment plant. As three representative markers of ICD, the expression of CRT, the efflux of HMGB1 from the tumor cell nucleus, and the secretion of ATP were evaluated, were critical for activating the adaptive immune response and anti-tumor T cell immunity.[24] As the results were shown in Fig. 4c and d, the CRT expression on tumor surface after being treated with PLNP\textsuperscript{Cu} pH=6.5 increased to 68.57%, which was considerably 1.29-fold higher than that in the control group. However, the positive rate of CRT in the LOX group (~55.40%) was insignificantly increased compared with controls, indicating that intracellular H\textsubscript{2}O\textsubscript{2} was insufficient to trigger ICD. A similar result was confirmed in the immunofluorescence (Fig. 4e).

Additionally, HMGB1 are normally localized in the cellular nucleus, while the weak green fluorescence at cell nuclei in PLNP\textsuperscript{Cu} pH=6.5, demonstrating the large quantities of HMGB1 extracellular released compared with the PBS treatment cells (Fig. 4f). For ATP secretion, PLNP\textsuperscript{Cu} treatment resulted in a higher ATP in the cellular supernatant (Fig. 4g). Notably, it was Fenton-like chemistry driven by cuprous ions that were the main reason for ICD, based on the results of the lower ATP release in PLNP pH=6.5 group compared with PLNP\textsuperscript{Cu} pH=6.5 (Fig. S12). The evidence above suggested that the intracellular lactate treatment plant activated by PLNP\textsuperscript{Cu} converted to lactate to anti-tumor ·OH, thereby producing considerable effects on ICD induction in tumor cells, paving the way for anti-tumor immune responses.

As one of the components of innate immunity in the tumor microenvironment (TME), macrophages were the major immune component of leukocyte infiltration in the tumor.[25] Unfortunately, lactate efflux associated with lactate accumulation and acid microenvironment suppressed proliferation and inhibited macrophage M1 polarization.[3, 26] The markers (CD80, CD206) of RAW264.7 macrophages were analyzed by flow cytometric analysis to determine the polarization after stimulating by the PLNP\textsuperscript{Cu}. 1 µg·mL\textsuperscript{-1} of LOX was chosen as the safe dose concentration according to the results of the cytotoxicity experiments (Fig. S13). The results showed that expression of CD80\textsuperscript{+} (M1 macrophages marker) on the cell surface significantly upregulated with the time increased of PLNP\textsuperscript{Cu} stimulation. Especially, it was up to 9.22% after 24 h of stimulation, which was 3-fold higher than the control group (Fig. 5a, c). However, the RAW264.7 macrophages displayed an insignificant change in M2-like polarization via analyzing the expression of intracellular CD206 (Fig. 5b, d). Again, immunofluorescence images revealed that the PLNP\textsuperscript{Cu} induced significant upregulation of the M1 biomarker CD80. (Green fluorescence signal of FITC labeled CD80, Fig. 5e). Collectively, these results demonstrated that PLNP\textsuperscript{Cu} induced macrophage M1
polarization in vitro through the consumption of extracellular lactate, which potentiated the antitumoral immune response.

2.5. Distribution and antitumor effects of PLNP\textsuperscript{Cu} \textit{in vivo}

PLNP\textsuperscript{Cu}@Cy7 was prepared to investigate the distribution of the PLNP\textsuperscript{Cu} in 4T1-bearing mice. The major organs (i.e., heart, liver, spleen, lung, and kidney) and tumors were collected within 1 h after tail vein injection of agents (Cy7-labeled LOX, PLNP\textsuperscript{Cu}@Cy7 respectively) for \textit{ex vivo} fluorescence imaging analysis. As shown in Fig. S14, free LOX indicated a non-specific distribution across the normal organs other than the tumor. In contrast, PLNP\textsuperscript{Cu}@Cy7 were significantly enriched in tumor tissues, which might be attributed to the enhanced permeability and retention (EPR) effect. And we observed the enrichment of PLNP\textsuperscript{Cu}@Cy7 in the liver was significantly lower than the free LOX, which decreased the immune-related adverse effects due to a nonspecific enrichment of LOX in the liver. In conclusion, these findings suggested that PLNP\textsuperscript{Cu} improved tumor targeting efficiency and accumulation, thereby decreasing the non-specific tissue distribution.

The antitumor effect and induction of systemic antitumor immune responses of PLNP\textsuperscript{Cu} were investigated in the 4T1 tumor-bearing mouse model (a weakly immunogenic tumor) (Fig. 6a). After 18 d of administration (five i.v. injections totally), the PLNP\textsuperscript{Cu} group exhibited the most effective tumor inhibition, while tumors showed similarly rapid growth in PBS and LOX groups (Fig. 6b, c). Specifically, PLNP\textsuperscript{Cu} demonstrating 88% tumor inhibition, the LOX only achieved 17%, and the moderate inhibitory of PLNP (37%) (Fig. S15). The tumor volume indicated that PLNP\textsuperscript{Cu} effectively inhibited tumor growth \textit{in vivo}. The same tendencies of body weight changes (Fig. 6d) and the no obvious tissue damage in H&E staining supported the safety of the PLNP\textsuperscript{Cu} treatment \textit{in vivo} (Fig. S16).

The effects of the lactate treatment plant PLNP\textsuperscript{Cu} established in the tumor treatment were further discussed in more detail. Tumor tissues were collected and the intratumoral lactate content was detected after five treatments with PBS, LOX, PLNP, and PLNP\textsuperscript{Cu}. The PLNP\textsuperscript{Cu} showed the lowest relative level of lactate (the fold of PBS) in the tumor, at only 0.48, which even reduced to half of the amount for the PBS or LOX group. The result of PLNP (0.79) indicated that thoroughly consumption and transition of intracellular lactate could counteract the active lactate metabolism in tumors, reflecting in the down-regulation of intra/extracellular lactate levels (Fig. 6e). In general, PLNP\textsuperscript{Cu} showed more effective lactate exhaustion than LOX or PLNP attributed to the effective tumor accumulation of nanoparticles and the well-functioning lactate treatment plant.

Although these experiments yielded good results, lactate consumption was only the first step of the lactate treatment plant. The generation of ·OH was quantified to validate the plant working properly. The generation of intracellular ROS in the tumor was detected by flow cytometry with the DCFH-DA probe. The MFI of the intracellular ROS in the PLNP\textsuperscript{Cu} group was 3 times higher than that of the PBS. There was no significant difference between the LOX and PLNP groups and, markedly, both were lower than the PLNP\textsuperscript{Cu}
group (Fig. 7c, d). The above results confirmed that the PLNP\textsuperscript{Cu} triggered the massive generation of intracellular ROS in 4T1 tumor cells. We estimated that the ROS was therefore mainly toxic ·OH that has a high affinity for DCFH-DA binding rather than H\textsubscript{2}O\textsubscript{2}.\cite{27} This conclusion was based on the minor amounts of ROS generation in PLNP group, specifically, the third step of the lactate treatment plant which is the Fenton-like reaction was disrupted due to the absence of copper ion. Incidentally, the limited cell uptake and the insufficient toxic ROS generation of free LOX also demonstrated the positive role of the continuous-operated lactate treatment plant in tumor inhibition. The abundant bright red fluorescence was observed in CLSM images of frozen tumor tissue sections, consistent with the flow cytometry results respectively (Fig. 7e). Together, the lactate treatment plant establishment triggered by PLNP\textsuperscript{Cu} exhibited the most effective lactate exhaustion and tumor inhibition.

### 2.6. Anti-tumor immune activation in vivo

Encouraged by the well-functioning lactate treatment plant in tumor, we subsequently monitored its anti-tumor immune responses. For this purpose, the typical cell types of cellular immunity (T cells) and innate immunity (macrophages) were detected. The percentage of cytotoxic T lymphocytes (CTL, CD3\textsuperscript{+}CD8\textsuperscript{+} T cells) infiltration in tumors after PLNP\textsuperscript{Cu} treatment was significantly increased compared with the PBS (4.06-fold higher) and PLNP (2.09-fold higher). There was a non-significant CTL proportion difference between LOX and PLNP groups. Although the slight upregulation of CTL was found in LOX (36.2%), PLNP\textsuperscript{Cu} showed the highest CTL proportion (1.30 times of LOX group) (Fig. 7b). The same results were observed in CLSM images, in which the copious green fluorescent signal at 488 nm confirmed higher CD8\textsuperscript{+} T cell infiltration in PLNP\textsuperscript{Cu} group (Fig. 7a). Furthermore, a typical cytokine (IFN-\gamma) of immune activation in tumor tissues was detected. As expected, tumor tissues of PLNP\textsuperscript{Cu} group presented the highest level of IFN-\gamma after treatment (Fig. S17). As it is well known, lactate production by cancer cells affects M2-like TAM polarization, which was associated with tumor growth, metastasis, and immunosuppression.\cite{3, 28} According to tumor infiltration macrophages analysis, M2 macrophages showed no obvious changes in number among all groups, while there was a significant increase in M1-like macrophages in PLNP treatment (Fig. S18). All the above results suggested that immune response activation at the tumor site was triggered through the establishment of the “lactate treatment plant” by PLNP\textsuperscript{Cu}.

The systemic anti-tumor immune response induced by PLNP\textsuperscript{Cu} was also explored. The spleen, containing abundant immune cells, is the largest immune organ and the immune center of the body in supporting anti-tumor immune response activation.\cite{29} We analyzed the phenotype and quantity of spleen T lymphocytes. As shown in the flow cytometry results, CD8\textsuperscript{+} T cells significantly increased in PLNP\textsuperscript{Cu} treatment group, the proportion of CD4\textsuperscript{+} T cells showed to be downregulated (Fig. 8a). Remarkably, PLNP\textsuperscript{Cu} increased the ratio of CD8\textsuperscript{+}/CD4\textsuperscript{+} T cells from 0.47 of PBS to 0.69 (Fig. 8d). Dendritic cells (DCs) present the tumor antigen to T cells, playing critical roles in pathogen sensing and initiation of anti-tumor immune responses. The DC maturation in draining lymph nodes (DLNs) including tumor DLNs was analyzed via flow cytometry. By qualitative and quantitative assays, the expressions of the DC maturation
marker MHC-II, CD86, and CD80 were up-regulated, confirming PLNP\textsuperscript{Cu} promotes DC maturation in DLNs (Fig. 8b, c, e and f). Together, all the immune analysis results suggesting that PLNP\textsuperscript{Cu} activated the immune system for efficient inhibition of tumor cell growth.

3. Conclusion

In summary, a pH-responsive nanosystem PLNP\textsuperscript{Cu} was constructed with synergistic anti-tumor effects of the combinatorial treatment with both metabolic therapy and immunotherapy. PLNP\textsuperscript{Cu} delicately used the tumor cell physiology and tumor microenvironment to build the “lactate treatment plant”, where the raw materials (H\textsubscript{2}O\textsubscript{2} that the enzymatic products of LOX, cuprous ions from nanosystem) processed into toxic \cdot OH products through Fenton-like reactions for further ICD, and then the immune system was activated for tumor inhibition. Meanwhile, the intra/extracellular lactate exhaustion remodeled the immunosuppressive TME, inducing TAM polarization to M1 and arousing the activity of immune cells around the tumor cells. Importantly, the 88% tumor inhibition was achieved with the PLNP\textsuperscript{Cu} treatment alone without the introduction of additional agents.

Declarations

Acknowledgments

Not applicable.

Authors’ contributions

RH and JZ contributed equally to this work. RH designed the research. RH and JZ developed methods, analyzed data, organized figures, wrote the manuscript, and performed most of the experiments. YL, SR, GC, DX, YY, YY, TZ and JG participated in the animal experiments. RH drew the scheme. YZ, XZ, HD and YL reviewed and revised the manuscript. All authors read and approved the final manuscript.

Funding

This work was financially supported through grants from the National Natural Science Foundation of China (51773154, 31771090), Shanghai Science and Technology Innovation (18JC1414500) and Young Hundred-Talent Program of Tongji University.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its additional information files.

Ethics approval and consent to participate
All animal procedures in compliance with the guidelines of the Institutional Animal Care and Use Committee of Tongji University (TJAA07721102).

**Consent for publication**

All authors agreed to publish this manuscript.

**Competing interests**

The authors declare no conflict of interest.

**References**

1. Mbeunkui F, Johann DJ: *Cancer and the tumor microenvironment: a review of an essential relationship*. *Cancer Chemotherapy and Pharmacology* 2009, 63:571-582.
2. Doherty JR, Cleveland JL: *Targeting lactate metabolism for cancer therapeutics*. *Journal of Clinical Investigation* 2013, 123:3685-3692.
3. Certo M, Tsai CH, Pucino V, Ho PC, Mauro C: *Lactate modulation of immune responses in inflammatory versus tumour microenvironments*. *Nature Reviews Immunology* 2020, 21:151-161.
4. Romero-Garcia S, Moreno-Altamirano MMB, Prado-Garcia H, Javier Sanchez-Garcia F: *Lactate Contribution to the Tumor Microenvironment: Mechanisms, effects on immune Cells and Therapeutic Relevance*. *Frontiers in Immunology* 2016, 7.
5. Hirschhaeuser F, Sattler UGA, Mueller-Klieser W: *Lactate: A Metabolic Key Player in Cancer*. *Cancer Research* 2011, 71:6921-6925.
6. Kolb D, Kolishetti N, Sumar B, Sarkar S, Guin S, Shah AS, Dhar S: *Metabolic Modulation of the Tumor Microenvironment Leads to Multiple Checkpoint Inhibition and Immune Cell Infiltration*. *ACS Nano* 2020, 14:11055-11066.
7. Li K, Lin C, He Y, Lu L, Xu K, Tao B, Xia Z, Zeng R, Mao Y, Luo Z, Cai K: *Engineering of Cascade-Responsive Nanoplatform to Inhibit Lactate Efflux for Enhanced Tumor Chemo-Immunotherapy*. *ACS Nano* 2020, 14:14164-14180.
8. Tang J, Meka AK, Theivendran S, Wang Y, Yang Y, Song H, Fu J, Ban W, Gu Z, Lei C, et al: *Openwork@Dendritic Mesoporous Silica Nanoparticles for Lactate Depletion and Tumor Microenvironment Regulation*. *Angewandte Chemie International Edition in English* 2020, 59:22054-22062.
9. Gao F, Tang Y, Liu WL, Zou MZ, Huang C, Liu CJ, Zhang XZ: *Intra/Extracellular Lactic Acid Exhaustion for Synergistic Metabolic Therapy and Immunotherapy of Tumors*. *Advanced Materials* 2019, 31:e1904639.
10. Zhou X, Zhao W, Wang M, Zhang S, Li Y, Hu W, Ren L, Luo S, Chen Z: *Dual-Modal Therapeutic Role of the Lactate Oxidase-Embedded Hierarchical Porous Zeolitic Imidazolate Framework as a*
Nanocatalyst for Effective Tumor Suppression. *Acs Applied Materials & Interfaces* 2020, **12**:32278-32288.

11. Wang H, Cheng L, Ma S, Ding L, Zhang W, Xu Z, Li D, Gao L: **Self-Assembled Multiple-Enzyme Composites for Enhanced Synergistic Cancer Starving-Catalytic Therapy**. *Acs Applied Materials & Interfaces* 2020, **12**:20191-20201.

12. Tseng SJ, Kempson IM, Huang KY, Li HJ, Fa YC, Ho YC, Liao ZX, Yang PC: **Targeting Tumor Microenvironment by Bioreduction-Activated Nanoparticles for Light-Triggered Virotherapy**. *Acs Nano* 2018, **12**:9894-9902.

13. Reyes-De-Corcuera JI, Olstad HE, Garcia-Torres R: **Stability and Stabilization of Enzyme Biosensors: The Key to Successful Application and Commercialization**. *Annual Review of Food Science and Technology* 2018, **9**:293-322.

14. Mei X, Hu TT, Wang H, Liang RZ, Bu WB, Wei M: **Highly dispersed nano-enzyme triggered intracellular catalytic reaction toward cancer specific therapy**. *Biomaterials* 2020, **258**.

15. Huang Z, Yao D, Ye Q, Jiang H, Gu R, Ji C, Wu J, Hu Y, Yuan A: **Zoledronic Acid-Gadolinium Coordination Polymer Nanorods for Improved Tumor Radioimmunotherapy by Synergetically Inducing Immunogenic Cell Death and Reprogramming the Immunosuppressive Microenvironment**. *ACS Nano* 2021, **15**:8450-8465.

16. Zhao HY, Wang YJ, Wang YB, Cao TC, Zhao GH: **Electro-Fenton oxidation of pesticides with a novel Fe3O4@Fe2O3/activated carbon aerogel cathode: High activity, wide pH range and catalytic mechanism**. *Applied Catalysis B-Environmental* 2012, **125**:120-127.

17. Brillas E, Banos MA, Camps S, Arias C, Cabot PL, Garrido JA, Rodriguez RM: **Catalytic effect of Fe2+, Cu2+ and UVA light on the electrochemical degradation of nitrobenzene using an oxygen-diffusion cathode**. *New Journal of Chemistry* 2004, **28**:314-322.

18. Wu GY, Fang YZ, Yang S, Lupton JR, Turner ND: **Glutathione metabolism and its implications for health**. *Journal of Nutrition* 2004, **134**:489-492.

19. Bansal A, Simon MC: **Glutathione metabolism in cancer progression and treatment resistance**. *Journal of Cell Biology* 2018, **217**:2291-2298.

20. Ma B, Wang S, Liu F, Zhang S, Duan J, Li Z, Kong Y, Sang Y, Liu H, Bu W, Li L: **Self-Assembled Copper-Amino Acid Nanoparticles for in Situ Glutathione "AND" H2O2 Sequentially Triggered Chemodynamic Therapy**. *Journal of the American Chemical Society* 2019, **141**:849-857.

21. Wu HS, Chen FH, Gu DH, You CQ, Sun BW: **A pH-activated autocatalytic nanoreactor for self-boosting Fenton-like chemodynamic therapy**. *Nanoscale* 2020, **12**:17319-17331.

22. Chen F, Chen JN, Yang LB, Liu J, Zhang XQ, Zhang Y, Tu QQ, Yin D, Lin DC, Wong PP, et al: **Extracellular vesicle-packaged HIF-1 alpha-stabilizing IncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells**. *Nature Cell Biology* 2019, **21**:498-510.

23. Ma PA, Xiao HH, Yu C, Liu JH, Cheng ZY, Song HQ, Zhang XY, Li CX, Wang JQ, Gu Z, Lin J: **Enhanced Cisplatin Chemotherapy by Iron Oxide Nanocarrier-Mediated Generation of Highly Toxic Reactive Oxygen Species**. *Nano Letters* 2017, **17**:928-937.
24. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G: **Immunogenic cell death in cancer and infectious disease.** *Nature Reviews Immunology* 2017, **17**:97-111.

25. Kondratova M, Czerwinska U, Sompairac N, Amigorena SD, Soumelis V, Barillot E, Zinovyev A, Kuperstein I: **A multiscale signalling network map of innate immune response in cancer reveals cell heterogeneity signatures.** *Nature Communications* 2019, **10**.

26. Lovisa S, LeBleu VS, Tampe B, Sugimoto H, Vadvagara K, Carstens JL, Wu CC, Hagos Y, Burckhardt BC, Pentcheva-Hoang T, et al: **Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis.** *Nature Medicine* 2015, **21**:998-1009.

27. Zhang L, Wan SS, Li CX, Xu L, Cheng H, Zhang XZ: **An Adenosine Triphosphate-Responsive Autocatalytic Fenton Nanoparticle for Tumor Ablation with Self-Supplied H2O2 and Acceleration of Fe(III)/Fe(II) Conversion.** *Nano Letters* 2018, **18**:7609-7618.

28. Tsai CS, Chen FH, Wang CC, Huang HL, Jung SM, Wu CJ, Lee CC, McBride WH, Chiang CS, Hong JH: **Macrophages from irradiated tumors express higher levels of iNOS, Arginase-I and COX-2, and promote tumor growth.** *International Journal of Radiation Oncology Biology Physics* 2007, **68**:499-507.

29. Yang J, Wang B, Zhang CF, Xu XH, Zhang M: **A C-21-Steroidal Glycoside from Cynanchum atratum Attenuates Concanavalin A-Induced Liver Injury in Mice.** *Molecules* 2019, **24**.

**Figures**
Figure 1

Characterization of PLNPCu. a, b TEM images of PLNPCu at pH 7.4. c DLS of PLNPCu at pH 7.4. d The pH-triggered charge rebound behavior of PLNPCu (n = 3). e The pH-responsiveness of PLNPCu. f Maintenance of size stability of PLNPCu in PBS and PBS with 5% FBS (at pH 7.4) (n = 3). g LOX loading capacities on LNP and LNPCu respectively (n = 3). h Cumulative release of LOX from PLNPCu in PBS at pH 7.4 and pH 6.5 (n = 3). i Hemolysis ratio of PLNPCu at different PEI concentrations. Results were expressed as mean ± SD. The significant difference was calculated via two-tailed t-test analysis (g). (NS represented not significant, *p <0.05, **p <0.01, ***p < 0.001).
Figure 2

Functions verification of lactate treatment plant PLNPCu in vitro. a Lactate adsorption ratio of PEI in nanoparticles (n = 3). b Lactate depletion effect of LNPCu over time at pH 7.4. c Lactate degradation ratio of LNPCu at the shorter incubation time in different acidic solutions (n = 3). d Lactate degradation ratio of LNPCu compared with LOX after sufficiently enzymatic hydrolysis (n = 3). e The generation of enzymatic product H2O2 (n = 3). f The degradation process of MB caused by ·OH generation from the Fenton-like reaction of nanoparticles under different conditions. Results were expressed as mean ± SD. The significant difference was calculated via one-way ANOVA analysis (a, d, e). (NS represented not significant, *p < 0.05, **p < 0.01, ***p < 0.001).
Figure 3

Intracellular behaviors of PLNPCu. a The cytotoxicity of PLNPCu and LOX against 4T1 cells (n = 5). b The flow cytometry analysis of cellular uptake of different agents (LOX@FITC, LNPCu@FITC, PLNPCu@FITC pH=7.4 and PLNPCu@FITC pH=6.5) after 3 h of incubation with 4T1 cells. c The lactate consumption analysis in 4T1 cell supernatant after treatment with PLNPCu. d Fluorescent microscopy image of intracellular ROS generation. Scale bars, 100 μm. e, f The flow cytometry analysis of ROS generation after treatment with PBS, LOX, PLNPCu pH=6.5 and PLNPCu pH=7.4. Results were expressed as mean ± SD. The significant difference was calculated via one-way ANOVA analysis (b, c, f). (NS represented not significant, *p <0.05, **p <0.01, ***p < 0.001).
Figure 4

ICD induction effects of PLNPCu in vitro. a, b Flow cytometric analysis of apoptosis rate of 4T1 cells after treatment with PBS, LOX, PLNPCu pH=7.4 and PLNPCu pH=6.5. c, d The flow cytometric analysis and quantitative results of relative fluorescence intensity of CRT on 4T1 cells. e Fluorescent microscopy image of CRT exposure. Scale bars, 100 μm. f Fluorescent microscopy image of HMGB1 outflow from the nucleus. Scale bars, 100 μm. g The ATP secretion from cancer cells after different treatments. Results were expressed as mean ± SD. The significant difference was calculated via one-way ANOVA analysis (b, d, g). (NS represented not significant, *p <0.05, **p <0.01, ***p < 0.001).
Figure 5

Immunomodulatory effects on macrophages of PLNPCu in vitro. a, c The flow cytometric analysis and quantitative results of surface markers CD80 (M1 macrophages marker) on RAW264.7 macrophages after incubation with PLNPCu for different times (3, 6, 24 h). b, d The flow cytometric analysis and quantitative results of surface markers CD206 (M2 macrophages marker) on RAW264.7 macrophages after treatment. e Immunofluorescence examination of RAW264.7 macrophages after incubation with PLNPCu for 24 h. Scale bars, 100 μm. Results were expressed as mean ± SD. The significant difference was calculated via one-way ANOVA analysis (c, d). (NS represented not significant, *p < 0.05, **p < 0.01, ***p < 0.001).
Figure 6

Antitumor effects of PLNPCu in vivo. a The treatment scheme of PLNPCu. b, c Individual tumor growth curves and average tumor growth curves of the mice with different treatments. d Body weight of the mice during the therapy. e The lactate consumption effect after treatment in vivo. Results were expressed as mean ± SD. The significant difference was calculated via one-way ANOVA analysis (c, e). (NS represented not significant, *p < 0.05, **p < 0.01, ***p < 0.001).
Figure 7

Immunogenic CDT induced an immune-active TME in vivo. a Immunofluorescence staining of intratumor infiltrating CD8+T cells after treatments with PBS, LOX, PLNP and PLNPCu. Scale bars, 100 μm. b The flow cytometry analysis of tumor infiltration of CD3+CD8+T cells. c, d The flow cytometry analysis of ROS generation after treatments. e Immunofluorescence staining of intratumor ROS generation. Scale...
bars, 100 μm. Results were expressed as mean ± SD. The significant difference was calculated via one-way ANOVA analysis (b, c). (NS represented not significant, *p < 0.05, **p < 0.01, ***p < 0.001).

Figure 8

Immune activation by PLNPCu in vivo. a The flow cytometric images of the CD4+T cells and CD8+T cells in spleen (gated on CD3+T cells). b The flow cytometric images of the CD80+CD86+ DCs in LNs (gated on CD11+ DCs). c The flow cytometric images of the CD86+MHC class II+ DCs in LNs (gated on CD11+ DCs). d
The flow cytometric quantification of the ratio of CD8+/CD4+ T cells in spleen. e The flow cytometric quantification of the CD86+CD80+ DCs in LNs. f The CD86+MHC II+ DCs in LNs. Results were expressed as mean ± SD. The significant difference was calculated via one-way ANOVA analysis (d, e, f). (NS represented not significant, *p <0.05, **p <0.01, ***p < 0.001).

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- GraphicalabstractimageJournalofnanobiotechnology.png
- scheme2.png
- SupportingInformationJournalofnanobiotechnology.docx